Ev Pembro

Emerging Targets in Bladder Cancer: EV Pembro, HER2, and ADC Therapies in Focus

GU Oncology Now

How Will EV, Pembrolizumab Combination Change the Bladder Cancer Treatment Landscape?

GU Oncology Now

EVITA Criteria to Identify Patients Unfit for EV/Pembro

GU Oncology Now

5-year follow-up of EV and pembrolizumab for la/mUC in the EV-103 trial

EV-103: EV with pembrolizumab in cisplatin-ineligible urothelial carcinoma

Enfortumab Vedotin Plus Pembrolizumab: Results of the EV-302 Trial With Thomas Powles, MD

Oncology Data Advisor

Breakthrough in Bladder Cancer: FDA approval - Enfortumab Vedotin + Pelbrolizumab with Dr.Tom Powles

OncBrothers: Practice-Changing Cancer Discussions

Uromigos Live 2023: Dr. Stephanie Berg on Best Treatment After EV/Pembro for mUC

GU Oncology Now

EV-103 Cohort K: enfortumab vedotin +/- pembro in untreated cis-ineligible patients with mUC

Initial EV-103 results: enfortumab vedotin plus pembrolizumab for urothelial carcinoma

Enfortumab vedotin plus pembrolizumab improves overall survival for advanced bladder cancer

Lecture on Cancer [ Coffee/ cancer; EV Pembro; Censoring] to UCSF Fresno

Vinay Prasad MD MPH

EVITA Criteria: Opening Doors for Novel Therapies in EV/Pembro-Ineligible Patients #cancer #news

GU Oncology Now

EV-103 Study by Dr. Jonathan Rosenberg led to the FDA Approval of Enfortumab + Pembrolizumab

OncBrothers: Practice-Changing Cancer Discussions

Treatment in the Post-EV/PEMBRO Setting #cancer #cancertreatment #cancerawareness #bladdercancer

GU Oncology Now

Rising Stars Session: Standard of Care Post-EV/Pembro, Treatment Rechallenging Considerations

GU Oncology Now

Treatment landscape after progression on Enfortumab + Pembro in bladder cancer

OncBrothers: Practice-Changing Cancer Discussions

Phase II trial of pembro & epacadostat in patients with recurrent clear cell carcinoma of the ovary

Cancer immunotherapy | The PD-L1 pathway

Evaluating futibatinib, EV and DV with pembrolizumab in urothelial carcinoma